Browse Articles

Discover research articles across all indexed journals

DNA-PKcs inhibitor causes genomic alterations

Nature Reviews Drug Discovery Sarah Crunkhorn Feb 01, 2025 DOI: 10.1038/d41573-025-00004-2

Spatiotemporal simulation of blue-green space pattern evolution and carbon storage under different SSP-RCP scenarios in Wuhan

Scientific Reports Guiyuan Li, Wangzhen Wang, Bowen Li et al. Feb 01, 2025 DOI: 10.1038/s41598-025-88299-4

Betagenin ameliorates diabetes by inducing insulin secretion and β-cell proliferation

Journal of Biological Chemistry Tomotaka Yokoo, Kazuhisa Watanabe, Kaoruko Iida et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2025.108202

Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: A single-arm phase II trial.

Journal of Clinical Oncology Yuwen Zhou, Wenjian Meng, Meng Qiu Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.201

201 Background: To evaluate the safety and efficacy of neoadjuvant chemotherapy (NAC) with three drug-intensity chemotherapy (oxaliplatin, irinotecan, and fluorouracil [FOLFOXIRI]) in patients with high-risk factors for recurrence and metastasis of locally advanced colon cancer (hr-LACC). Methods: A single-arm, open-label, phase II trial was conducted at West China Hospital of Sichuan University from July 2020 to Oct 2023. Patients with T4a/b or (and) N2/fused lymph nodes) and no distant metastases were considered as the hr-LACC patients. Eligible enrolled patients received four cycles of NAC with FOLFOXIRI followed by surgery and adjuvant chemotherapy with capecitabine and oxaliplatin (CAPOX) for two to five cycles or single-agent capecitabine for five cycles or observation. The primary endpoint was the rate of TRG grade 0-2 according to the criteria of NCCN guideline. Results: Of 72 patients enrolled (median age 53 [18-74] years,65 were T4a/b [90.2%], 66 were N2 [91.6%]), 58 patients (80.6%) completed four cycles of FOLFOXIRI. Three patients (4.2%) achieved clinical complete response. Twenty-eight patients (39.4%) obtained clinical partial response. The most common adverse event (AE) was nausea (86.1%, 62/72); grade 3-4 AEs occurred in 37 of 72 patients (51.4%).R0 resection was achieved in 64 of 64 patients, and the TRG (0-2) rate was 87.5% (56/64). The pathologic complete response rate was 7.8% (5/64). The proportions of pT0-2 and pN0 were 21.9% and 68.8%, respectively. Only three (4.7%) patients had prolonged hospital stay due to perioperative complications. No patient died within 30 days and 90 days after surgery. The 2-year tumor recurrence rate was 17.2%. Conclusions: For patients with hr-LACC, NAC with FOLFOXIRI regimen was safe and effective. Longer follow-up and larger clinical studies are needed to validate this innovative regimen. Clinical trial information: NCT05018182 .

The impact of protein-energy malnutrition on clinical outcomes in hospitalized gastric cancer patients: A population-based analysis.

Journal of Clinical Oncology Rabia Iqbal, Henry Kimball, Mrunanjali Gaddam et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.503

503 Background: Protein-energy malnutrition (PEM) is considered an adverse prognostic factor in various clinical conditions. Patients with gastric cancer are at an increased risk of malnutrition because of factors such as loss of appetite due to the tumor, difficulty swallowing, malabsorption, and metabolic changes caused by the cancer. However, the implications of protein-energy malnutrition (PEM) in gastric cancer patients are not well studied. Through this study, we wanted to examine how PEM affects clinical outcomes in hospitalized patients with gastric cancer. Methods: We used the National Inpatient Sample (NIS) from 2018 to 2020 to detect patients with a primary diagnosis of gastric cancer and a secondary diagnosis of protein energy malnutrition (PEM). We used the chi-square and student T-test to analyze categorical and continuous variables. Confounders were adjusted using multivariable regression analysis, and the adjusted odds ratio (aOR) was calculated. Results: We detected a total of 1673915 patients with the primary diagnosis of gastric cancer using ICD-10 codes. Of them, 401,739 (24%) of the patients had a secondary diagnosis of PEM. The mean age of the patients was 66 years (p-value <0.01). Of these, 56% of the patients were male, while the remaining 44% were female (p-value <0.001). Based on race, 68% of the patients belonged to the White Race, 12% were African Americans, and 11% were Hispanics (p-value <0.001). It was observed that the presence of PEM was associated with higher mortality (aOR 1.6, p-value <0.001). There was also higher hospitalization cost ($109522 vs. 75725, p-value <0.001) and mean length of stay (LOS) (9.1 days vs. 5.6 days, p-value <0.001). PEM in gastric cancer patients was also associated with higher odds of sepsis (aOR 1.6, p-value <0.001), gastritis (aOR aOR 1.2, p-value <0.001), gastrointestinal (GI) bleeding (aOR 1.1, p-value <0.001) and acute kidney injury (AKI) (aOR 1.7, p-value <0.001). Conclusions: Our study demonstrates that protein-energy malnutrition (PEM) is associated with increased mortality, higher hospitalization costs, and longer stays in hospitalized gastric cancer patients. These findings emphasize the need for regular nutritional assessment and management to improve clinical outcomes in this population. Comparison of outcomes in hospitalized gastric cancer patients with and without protein-energy malnutrition (PEM). Hospital Outcomes Gastric Cancer Patients with PEM Gastric Cancer Patients without PEM Adjusted Odds ratio (aOR) 95% Confidence Interval P-value Mortality 9.1% (n=36999) 5.3% (n=68100) 1.6 1.5-1.7 <0.001 Length of Stay 9.1 5.6 3.0 2.7-3.3 <0.001 Sepsis 10% (n=41915) 6.4% (n= 82035) 1.6 1.5-1.6 <0.001 Gastritis 3.9% (n=16174) 3.3% (n=41879) 1.2 1.1-1.31 <0.001 GI Bleeding 7.1% (n= 28949) 6% (n= 28949) 1.1 1.0-1.2 <0.001 AKI 28% (n=117439) 19% (n=1268134) 1.7 1.7-1.8 <0.001

Real-world validation of the Khorana risk score in gastric cancer patients receiving immune checkpoint inhibitors.

Journal of Clinical Oncology Junmin Song, Wing Fai Li, Chaeseong Yim et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.363

363 Background: Thrombosis is a common cancer-related complication, particularly in gastric cancer. Studies show that immune checkpoint inhibitors (ICIs) increase the risk of venous thromboembolism (VTE) and arterial thrombosis. The Khorana risk score is widely used to assess thrombosis risk before starting chemotherapy. This study aimed to validate the Khorana score in gastric cancer patients receiving ICIs using a large global database. Methods: We used the TriNetX Global Collaborative Network, which contains de-identified data from over 120 million patients. We included patients diagnosed with gastric cancer who received ICIs between January 2014 and July 2023. The Khorana risk score was calculated based on lab values and BMI within two weeks before ICI initiation. Patients were divided into two cohorts: elevated risk (score 3-6) and intermediate risk (score 2). Cox-proportional hazard analyses were conducted over a one-year follow-up. The primary outcome was VTE (deep vein thrombosis [DVT] and pulmonary embolism [PE]). Secondary outcomes were arterial thrombosis, including myocardial infarction (AMI) and ischemic stroke, and all-cause mortality. Results: The study included 551 patients, with 362 in the intermediate risk and 189 in the elevated risk cohorts. The mean age was 64 in both cohorts, with the elevated group consisting of more males (76% vs. 63%) and a higher proportion of Black patients (11% vs. 6%). Pembrolizumab (49%) and nivolumab (47%) were the most used ICIs. Patients with elevated risk had a significantly higher risk of VTE (HR 1.74, 95% CI 1.18-2.58), DVT (HR 1.82, 95% CI 1.07-3.10), and PE (HR 1.74, 95% CI 1.07-2.84). However, no significant associations were found with arterial thrombosis (HR 1.28, 95% CI 0.74-2.20), including cerebral infarction (HR 1.05, 95% CI 0.51-2.16), or AMI (HR 1.46, 95% CI 0.70-3.05). The elevated risk cohort also had significantly higher mortality (HR 1.44, 95% CI 1.11-1.87). Conclusions: An elevated Khorana risk score is associated with a higher risk of VTE, but not arterial thrombosis, in gastric cancer patients treated with ICIs. Further studies are needed to determine how the Khorana score can be applied to predict ICI-related thrombosis and guide prophylactic anticoagulation. Outcomes Khorana risk score 3-6 Khorana risk score 2 Hazard ratio(95% CI) P-value(Log-rank) At risk patients Cases At risk patients Cases Venous thromboembolism 189 45 362 58 1.74 (1.18-2.58) 0.005 Deep vein thrombosis 189 25 362 30 1.82 (1.07-3.10) 0.025 Pulmonary embolism 189 29 362 36 1.74 (1.07-2.84) 0.025 Arterial thrombosis 189 21 362 34 1.28 (0.74-2.20) 0.375 Cerebral infarction 189 11 362 22 1.05 (0.51-2.16) 0.901 Acute myocardial infarction 189 12 362 17 1.46 (0.70-3.05) 0.317 All-cause mortality 189 93 362 145 1.44 (1.11-1.87) 0.006

Longitudinal ctDNA measurements for treatment response monitoring in patients with metastatic colorectal cancer undergoing systemic therapy: The ORCA trial.

Journal of Clinical Oncology Denise van Steijn, George Laliotis, Erik Anthony Spickard et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.220

220 Background: Precise monitoring of treatment response may support and improve treatment decision-making in patients with metastatic colorectal cancer (mCRC). The PLCRC-ORCA study aimed to explore the clinical applicability of personalized ctDNA testing for treatment response monitoring in patients with mCRC. Methods: The prospective, observational ORCA study is a substudy of the Prospective Dutch ColoRectal Cancer cohort (PLCRC). After informed consent, blood samples were collected before initiating first line of treatment (baseline) and subsequently every 8-9 weeks during routine clinical care. ctDNA levels were analyzed using a clinically validated, personalized, tumor-informed 16-plex PCR NGS assay (Signatera™, Natera, Inc). Results: The majority of patients (45/49) had blood samples collected at both baseline and the first on-treatment time point. At baseline, 43/45 (95.6%) patients were ctDNA-positive with a median concentration of 63.5 mean tumor molecules per mL (MTM/mL; range 0.08 to 16,200). In a multivariate linear regression model including metastatic site at baseline and resection status of the primary tumor, ctDNA levels at baseline were lower in patients with metastatic disease limited to the lung (n = 4; p < 0.001) or peritoneum (n = 6; p = 0.002) compared to patients with liver-limited metastases. Moreover, primary tumor resection was independently associated with lower levels of ctDNA at baseline (p = 0.05). At the first measurement on-treatment, 13/45 patients (28.9%) were ctDNA-negative and 32/45 (71.1%) patients were ctDNA-positive with ctDNA levels ranging from 0.04 to 318 MTM/mL. Reduction in ctDNA levels relative to baseline was observed in 42/45 (85.7%) patients while two patients exhibited increased ctDNA levels. One patient had undetectable ctDNA levels at baseline and on treatment. Among the 30 patients with detectable but reduced ctDNA levels on treatment, the median ctDNA levels decreased 55-fold (95% CI: 26–600). Conclusions: The levels of ctDNA in patients with mCRC are influenced by the metastatic site and are lowest among patients with metastases limited to the lung and peritoneum. Our data suggest that clinical applications of ctDNA testing for treatment response monitoring should take the baseline ctDNA levels into account when interpreting ctDNA dynamics. Correlation of ctDNA status with radiological treatment response is underway and will be reported during the conference.

Engineered T cells traverse new terrain

Nature Reviews Drug Discovery Katie Kingwell Feb 01, 2025 DOI: 10.1038/d41573-025-00002-4

Study on the effects of fissure geometric characteristics on the mechanical behavior and failure mechanism of granite under uniaxial compression test

Scientific Reports Zhaolong Sang, Donghui Ma, Yaoyao Meng et al. Feb 01, 2025 DOI: 10.1038/s41598-025-88278-9

Receptor-independent regulation of Gα13 by alpha-1-antitrypsin C-terminal peptides

Journal of Biological Chemistry Yonghak Park, Shigeyuki Matsumoto, Kosuke Ogata et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108136

Real-world assessment of MDM2 amplification and survival among patients with advanced or metastatic biliary tract cancer in the United States.

Journal of Clinical Oncology Renuka Iyer, Kathryn Evans, Alyssa B Klein et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.544

544 Background: There are few real-world studies on biliary tract cancer (BTC), especially those related to biomarkers for potential novel targeted therapies. The aim of this study was to provide additional information of the prevalence of biomarkers, treatment patterns, and clinical outcomes of patients with BTC in the US, with a focus on patients with mouse double minute 2 homolog ( MDM2 ) amplified, tumor protein 53 wild type (TP53 WT) BTC. Methods: This was an observational cohort study using deidentified data from the Flatiron Health-Foundation Medicine BTC Clinico-Genomic Database, which included patients with advanced or metastatic BTC who underwent genomic analysis and received antineoplastic therapy in the US between January 1, 2013 and June 30, 2023. Three cohorts were created: 1) 1L+ cohort that included all patients that initiated 1 st line (1L) therapy during the study period, 2) 2L+ cohort that included all patients that initiated 2 nd line (2L) therapy during the study period, and 3) MDM2 amp + TP53 WT cohort that included patients in the 1L+ cohort that had MDM2 amplified (≥ 8 copies), TP53 WT. The prevalence of select biomarkers was assessed, as well as treatment patterns, and clinical outcomes including time to next therapy (TTNT) and overall survival (OS). Results: A total of 1,548 patients met the selection criteria for the 1L+ cohort, of whom, 875 initiated 2L therapy (2L+ cohort), and 55 had MDM2 amplified, TP53 WT BTC ( MDM2 amp + TP53 WT cohort). In the 1L+ cohort, 66 (4.3%) had MDM2 amplification and 872 (56.3%) had TP53 WT. The most common treatment regimens were cisplatin/gemcitabine (44.5%, 50.7%, 41.8% of patients in the 1L+, 2L+, and MDM2 amp + TP53 WT cohorts, respectively) at 1L and FOLFOX (12.9%, 22.9%, 16.4% of patients, respectively) at 2L. The median (95% CI) OS from start of 1L was 10.7 (10.0 – 11.3) months for the 1L+ cohort and 11.9 (10.4 – 17.7) months for the MDM2 amp + TP53 WT cohort. The median OS from the start of 2L was 8.0 (7.2 – 8.8) months for 2L+ cohort. Furthermore, the median TTNT was similar between 1L+ cohort and MDM2 amp + TP53 WT cohort, 5.3 (5.0 – 5.7) and 4.8 (4.0 – 7.6) months, respectively. The median TTNT from the start of 2L in the 2L+ cohort was 4.3 (3.8 – 4.6) months. We will present co-mutation data in MDM2 amp + TP53 WT cohort. Conclusions: The MDM2 amplification and TP53 WT status does not appear to be a prognostic biomarker in advanced/metastatic BTC with similar median TTNT and OS in the 1L+ and MDM2 amp + TP53 WT cohorts. Targeted treatments may help improve OS among these patients and thus further research into these treatments and how they impact survival is warranted.

Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study.

Journal of Clinical Oncology David Berz, Olatunji B. Alese, David S. Hong et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.129

129 Background: DR5, a proapoptotic receptor, is selectively expressed on tumor vs normal cells, making it an attractive target. DR5 binds to its ligand, TRAIL, resulting in DR5 multimerization and apoptosis; greater DR5 clustering enhances downstream effects. Ozekibart is a next-generation, recombinant, humanized, tetravalent DR5 agonist that is based on a single-domain antibody platform and precisely engineered to balance agonism and safety. Ozekibart previously demonstrated an acceptable safety profile and clinical benefit in chondrosarcoma (1), prompting a phase 2, randomized trial (ChonDRAgon; NCT04950075). An ongoing phase 1 study (NCT03715933) is evaluating ozekibart in various solid tumors, including 2L+ CRC, for which effective therapies are lacking. We present preliminary results of ozekibart + FOLFIRI in 2L+ CRC (data cutoff: Aug 9, 2024). Methods: Parts 1 (single-agent dose escalation) and 2 (single-agent dose expansion; recommended phase 2 dose [RP2D] ozekibart 3 mg/kg IV Q3W) of this 3-part, open-label trial are complete. Part 3 (combination dose expansion with chemo) is ongoing in pts with CRC, Ewing sarcoma, or SDH-deficient GIST. Pts with locally advanced or metastatic, unresectable CRC who received oxaliplatin-based chemo were eligible for part 3. Pts with chronic liver disease were ineligible. Pts in the part 3 CRC cohorts (N=13; enrollment complete) received ozekibart 1 mg/kg (n=5) or 3 mg/kg (n=8) IV Q28D (1 cycle) + FOLFIRI Q14D (FOLFIRI could be stopped after ≥6 cycles); in 4/5 pts, ozekibart dose was escalated to 3 mg/kg (RP2D). The primary endpoint is safety; clinical response is an exploratory endpoint. Results: In total, 13 pts with CRC (male, 62%) received ozekibart + FOLFIRI. Median age was 60. All pts had metastatic disease; median number of prior lines of therapy was 2 (range, 1-6). At data cutoff, 2 pts remained on treatment. Ozekibart-related adverse events (AEs) were reported in 85% of pts (grade ≥3, 31%) and led to ozekibart interruption in 3 pts and discontinuation in 1 pt. One combo-related AE (neutropenic sepsis) led to death. The most common ozekibart-related AEs were nausea (n=5) and diarrhea, fatigue, and increased alanine aminotransferase (each n=4). Four pts (31%) had responses (all partial). Disease control rate (response + stable disease) was 77% (10/13) and durable (>180 days) in 46% (6/13) of pts. Most pts had tumor shrinkage. Median PFS was 7.85 mo. Conclusions: Ozekibart + FOLFIRI showed encouraging preliminary efficacy, including PRs and durable disease control, as 2L+ therapy in pts with CRC. Given these promising data, a new expansion cohort (C4d) is open to validate these findings in a more homogeneous population. Eligible pts will have had 2 or 3 prior lines of systemic therapy (irinotecan allowed but not in the immediately prior line) and must have archival or fresh biopsy tissue. 1. Subbiah. Clin Cancer Res. 2023. Clinical trial information: NCT03715933 .

Redefining the use of a first-line FOLFIRINOX-like regimen in older patients with metastatic pancreatic cancer.

Journal of Clinical Oncology Arthur Winer, Dina Ioffe, Karen J Ruth et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.681

681 Background: Prospective elderly-specific data for treating pancreatic cancer are scarce. First-line treatment with triplet chemotherapy (e.g., FOLFIRINOX) is often too toxic for older adults (OA). An alternating regimen of FOLFOX and FOLFIRI (aFOLFIRINOX) has demonstrated efficacy and decreased toxicity in patients with colon cancer. This ongoing multicenter phase II trial evaluates the tolerability and efficacy of aFOLFIRINOX in OA with metastatic pancreatic adenocarcinoma (mPDAC). Herein we report the interim safety analysis results. Methods: Eligible patients (goal n=37) ≥65 years old with measurable untreated mPDAC, ECOG PS 0-2, receive standard doses of FOLFOX alternating with FOLFIRI every 2 weeks for up to 6 months. Patients can continue treatment thereafter at the discretion of their physician. The primary endpoint is rate of treatment-limiting grade ≥3 adverse events (TLAE) per CTCAE v5.0 in the first 8 weeks of therapy. These toxicities are defined as treatment-related grade 3 non-hematologic AE persisting > 2 weeks despite best supportive care, grade 3 anemia or thrombocytopenia, grade >3 neuropathy, or any grade > 4 AE. The study is powered to detect a 20% improvement in grade ≥3 TLAE: null vs alternate: 45% vs 65% of patients without TLAE at 8 weeks. Secondary endpoints include progression free & overall survival (PFS & OS) and objective response rate (ORR). FACT-G and PROMIS-10 quality of life (QOL) surveys and geriatric assessments are collected and will be correlated with treatment outcomes. Results: 21 eligible patients were included in the interim safety analysis: 11 male, 10 female; median age:73 (range 65-82); 18 patients had ECOG PS 0-1. 16 (76%) patients did not experience TLAE as defined above. TLAE included neutropenia, thromboembolism, and hypokalemia, and are similar to reported toxicity with FOLFOX and FOLFIRI in this patient population. One patient died of their disease within 8 weeks of treatment initiation and another within 2 weeks due to pulmonary embolism deemed unrelated to treatment. Of the 18 patients evaluable for response, ORR was 11% (partial response: n =2), Disease Control Rate was 89% (stable disease: n =14). 7 patients completed 6 months of treatment on study. Conclusions: The interim safety analysis of this clinical trial fulfilled the predefined futility rule without excess treatment-limiting or unexpected toxicity among OA with mPDAC treated with first-line aFOLFIRINOX, suggesting this may be a reasonable treatment option in this patient population. Trial is ongoing for evaluation of efficacy data of this regimen. Clinical trial information: NCT05360732 .

Phase II study of neoadjuvant FLOT and chemoradiation for trimodality therapy of esophageal/GEJ adenocarcinoma.

Journal of Clinical Oncology Jeffrey R. Olsen, Alexis Diane Leal, Sunnie S. Kim et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.466

466 Background: Recent data support use of perioperative FLOT (5-FU/leucovorin/oxaliplatin/docetaxel) chemotherapy over pre-operative chemoradiation (CRT) for patients with resectable esophageal/GEJ adenocarcinoma with limited studies evaluating combined FLOT/CRT. This prospective phase II study (NCT04028167) evaluated a neoadjuvant approach of FLOT followed by CRT for resectable esophageal/GEJ adenocarcinoma (EAC). Methods: Operable patients with cT1-2 N1-2 or cT3-4N any4 Nany non-metastatic EAC were eligible. Neoadjuvant treatment consisted of FLOT x 3 cycles followed by restaging PET and chemoradiation (41.4 Gy / 23 fractions to the primary site and regional lymphatics with weekly carboplatin/paclitaxel). Adjuvant nivolumab for non-pathologic complete response (pCR) was permitted. The primary endpoint was pCR rate among patients receiving the study regimen and undergoing resection, with secondary endpoints including disease free survival (DFS), overall survival (OS), toxicity, and correlative studies. DFS/OS was measured using the Kaplan Meier (KM) method. Interim results are presented after a planned safety analysis. Results: Since 4/2020, 23 patients with median age of 62 (range 40-73) have enrolled. cT3-4 and cN+ disease was present in 20/23 (87%) and 16/23 (70%) of patients, respectively. FLOT was completed by 21/23 patients (reasons for discontinuation included allergic reaction and G5 sepsis/endocarditis). All 21 patients initiating chemoradiation completed planned treatment and 17/21 underwent resection (2 refused surgery after achieving cCR, 1 died of cardiac arrest, 1 patient is awaiting surgery). A pCR was observed in 5/17 resected patients (29%), with pCR or near pCR observed in 9/17 (53%). The complete response rate (pCR + cCR for patients refusing surgery) was 7/19 (37%). Adjuvant nivolumab was administered in 9 patients. The median follow-up among all patients was 20 months with 2-year DFS and OS estimates of 61% and 73%. The regimen was tolerated with G3+ hematologic, G3+ gastrointestinal, and G3+ other toxicity observed in 39%, 13%, and 22% of patients, respectively. Conclusions: In a locoregionally advanced population, neoadjuvant sequential FLOT followed by CRT was well tolerated with encouraging DFS/OS and a high rate of complete response compared to prior studies. This hybrid platform may enhance both locoregional and distant control and is of interest for expanded evaluation. Clinical trial information: NCT04028167 .

Lipid nanoparticle ferries therapeutic mRNA to the placenta

Nature Reviews Drug Discovery Alex Eccleston Feb 01, 2025 DOI: 10.1038/d41573-025-00003-3

Predicting carbon dioxide emissions using deep learning and Ninja metaheuristic optimization algorithm

Scientific Reports Anis Ben Ghorbal, Azedine Grine, Ibrahim Elbatal et al. Feb 01, 2025 DOI: 10.1038/s41598-025-86251-0

Deafness-associated mitochondrial 12S rRNA mutation reshapes mitochondrial and cellular homeostasis

Journal of Biological Chemistry Yunfan He, Zhining Tang, Gao Zhu et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108124

Correlation of mesothelin (MSLN) expression measured by RNA sequencing (RNASeq) and immunohistochemistry (IHC) in MSLN-expressing tumors.

Journal of Clinical Oncology Joel R Hecht, Patrick Grierson, Theodore H. Welling et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.766

766 Background: BASECAMP-1 (NCT04981119) is a pre-screening study to identify patients with tumor-associated human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH) for interventional studies, such as EVEREST-2 (NCT06051695), a phase 1/2 study of logic-gated chimeric antigen receptor T-cell (CAR T) therapy for MSLN-expressing cancers. MSLN is a cell surface protein expressed in several cancer types, including mesothelioma (MESO), colorectal (CRC), non-small cell lung (NSCLC), ovarian (OVCA), and pancreatic (PANC) cancer, which can be associated with poor prognosis (1). Longitudinal clinical, genomic, and biomarker data were collected from patients enrolled in BASECAMP-1, providing a large dataset for translational discovery and propensity scoring. The aim of this analysis was to determine whether MSLN expression measured by RNAseq and IHC are correlated among patients with solid tumors. Methods: In BASECAMP-1, tumor tissue from patients with germline heterozygous HLA-A*02 is tested for HLA-A*02 LOH using an investigational next generation sequencing device codeveloped with Tempus Labs (Lozac'hmeur, et al. NPJ Precis Oncol. 2024) that detects somatic alterations, including HLA LOH, and generates RNAseq data (eg, MSLN expression). Gene-level transcripts per million read (TPM) values were determined and the log2 TPM +1 was displayed in a scatter plot (the mean and standard deviation [SD] are provided in the Table). Patients with HLA-A*02 LOH also submit tissue for IHC testing for exploratory biomarkers (eg, MSLN expression using anti-MSLN clone 5B2). Statistical significance was determined with ANOVA or t-tests. Results: As of June 1, 2024, 314 patients had been screened for BASECAMP-1 and had RNAseq results; 34 patients also had MSLN IHC results. MSLN expression by RNAseq was consistently higher in patients with PANC or OVCA vs CRC or NSCLC ( P <0.001). MSLN expression by RNAseq and IHC were correlated overall ( P <0.001), particularly among patients with PANC and OVCA. Among the 8 patients with OVCA or PANC who were IHC+ for MSLN, only 1 had an RNAseq value below 6 log2 TPM+1; this patient had mesonephric-like ovarian adenocarcinoma, which may account for the low value. The one MESO sample with both RNAseq and IHC available was IHC+ and had a high RNAseq value. Conclusions: This analysis demonstrated high correlation between RNAseq and IHC MSLN expression in tumor tissue. 1. Faust, et al. Cancers. 2022. Clinical trial information: NCT04981119 . MSLN expression by RNASeq by tumor type and IHC status. Tumor Overall (N=314) IHC data available (n=34) MSLN Positive MSLN Negative n Mean TPM a (SD) n Mean TPM a (SD) n Mean TPM a (SD) All 314 5.1 (2.3) 20 6.0 (2.1) 14 2.3 (1.7) adNSCLC 33 3.8 (2.4) 2 4.7 (1.7) 7 1.5 (1.3) sqNSCLC 4 3.1 (1.8) 0 0 MESO 4 4.5 (4.2) 1 5.7 0 CRC 148 4.4 (2.0) 8 5.1 (2.1) 7 3.1 (1.6) PANC 100 6.1 (1.8) 3 7.8 (0.6) 0 OVCA 25 7.2 (2.1) 5 6.6 (2.8) 0 a MSLN log2 transcripts per million+1. ad, adenocarcinoma; sq, squamous.

Identification of candidate biomarkers for gastric cancer by bioinformatics analysis of pooled microarray gene expression datasets in Gene Expression Omnibus.

Journal of Clinical Oncology Audrey Chen, Fen Wang Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.467

467 Background: Gastric cancer (GC) remains one of the most prevalent malignant diseases worldwide. The high mortality rate is largely due to the limited treatment options and the challenges in diagnosing the cancer at an early stage. Understanding the genetic differences driving the proliferation of GC is crucial for advancing diagnostic methods and developing targeted treatments. This study aims to identify biomarkers involved in the pathogenesis of GC through integrated bioinformatics analysis. Methods: Extracted from the Geo Expression Omnibus, three DataSets (GSE118916, GSE79973, and GSE13861) were analyzed for differentially expressed genes (DEGs) using the R statistical language. The three data sets were then compared for common DEGs, which would serve as the focus of this study. These DEGs were functionally analyzed for pathways by Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). A protein–protein interaction (PPI) network was constructed to screen out candidate genes. Results: The results revealed that 123 DEGs of the three datasets containing 26 upregulated genes and 97 downregulated genes were ascertained in our study. The GO and KEGG enrichment analysis results showed that the functions of DEGs were mainly involved in the retinol metabolic process, xenobiotic metabolic process, collagen type I trimer, potassium: proton exchanging ATPase complex, benzaldehyde dehydrogenase (NAD+) activity, alcohol dehydrogenase (NADP+) activity, Collecting duct acid secretion, and Tyrosine metabolism. Through the PPI analysis network, the core genes with the highest degree of 7 nodes were selected: COL1A1, COL1A2, COL11A1, THBS2, ATP4A, COL10A1, and CXCL8. Conclusions: The 7 genes identified in this study may play a vital regulatory role in the occurrence and development of GC and may also be potential therapeutic targets. Further mechanistic studies of the pathogenesis and treatment of GC may be able to identify new targets using these shared pathways. These findings could contribute to a better understanding of the origins of gastric cancer and facilitate the development of early interventions. The bioinformatics analysis conducted in this study offers new insights and directions for further research on gastric cancer.

A real-world prospective analysis of the relationship between nanoliposomal irinotecan and fluorouracil with folinic acid and neutropenia in patients with pancreatic cancer (NAPOLEON-2 study, NN-2401).

Journal of Clinical Oncology Tsuyoshi Shirakawa, Tomonori Araki, Mototsugu Shimokawa et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.762

762 Background: Nanoliposomal irinotecan and fluorouracil with folinic acid (NFF) is a standard regimen after gemcitabine-based chemotherapy (CTx) for unresectable or recurrent pancreatic cancer (urPC) patients. Neutropenia caused by systemic CTx has been reported to be a prognostic marker in several cancers, however, the relationship between neutropenia and efficacy of NFF in urPC patients is unknown. Therefore, we initiated a prospective observational study to investigate whether neutropenia can be a prognostic marker in the real-world (NN-2401), followed by a retrospective one (NN-2301). Methods: We collected the data of urPC patients treated with NFF who had received at least one previous CTx in 17 hospitals in Japan from June 2021 to October 2023. The primary endpoint was overall survival (OS). Secondary endpoints included the progression-free survival (PFS) and overall response rate (ORR). To analyze them, we divided urPC patients into three groups by the grade of the most severe neutropenia during NFF (Cutoff A, grade 0 vs 1-4; Cutoff B, grade 0-1 vs 2-4; Cutoff C, grade 0-2 vs 3-4). Besides that, we compared OS among the following three groups receiving NFF ≥4 cycles in Cutoff C; one showed neutropenia with NFF reduction after the 4th cycle (Cutoff C High-Late), another showed neutropenia with NFF reduction in the 2nd or 3rd cycle (Cutoff C High-Early), and the other did grade 0-2 neutropenia (Cutoff C Low). Results: Among the 150 patients, the number of patients with the most severe neutropenia of grade 0, 1, 2, 3, or 4 was 79, 7, 23, 34, and 7, respectively. The median OS of severe neutropenia group in Cutoff A, B, or C was 9.8, 9.8, and 10.6 months, respectively. Both OS and PFS were significantly better in all severe neutropenia groups; hazard ratio [HR] of OS for Cutoff A, B, or C was 0.58, 0.54, and 0.60, respectively; HR of PFS was 0.61, 0.56, and 0.56, respectively. Only Cutoff C showed a significant difference with an odds ratio of 3.06 (95% confidence interval [CI], 1.06-8.80; p=0.04) in ORR. Multivariate Cox regression analysis showed significant difference of OS in all Cutoffs; adjusted HR was 0.58 for Cutoff A, 0.53 for Cutoff B, and 0.52 for Cutoff C. Logistic regression analysis showed a significant difference in ORR of Cutoff C with an odds ratio of 4.02 (95%CI, 1.29-12.6; p=0.02). In addition, the numbers of patients were 73, 14, and 19 in Cutoff C Low, High-Late, and High-Early, respectively. The median OS of Cutoff C High-Late was significantly better than that of Cutoff C High-Early or Cutoff C Low (15.0 vs 10.4 or 9.1 months, p<0.05). Conclusions: In NFF treatment, neutropenia showed the usefulness as a prognostic marker for both OS and PFS, and also a predictive one for tumor response in urPC patients. The results are similar to our previous data, so we conclude that neutropenia can be a useful biomarker of NFF. Clinical trial information: UMIN000043939 .